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Cytokine-induced expression of leukemia inhibitory factor in renal
mesangial cells. Leukemia inhibitory factor (LIF) is a pleiotropic
cytokine, which shares many characteristics with interleukin-6 (IL-6).
Recent observations indicate a role for LIF in inflammatory processes.
To examine the potential involvement of LIF in the regulation of
mesangial cell behavior, we studied LIF expression in early primary
cultures of rat and human mesangial cells, as well as the response of
mesangial cells to exogenous LIF. Growing or growth-arrested rat
mesangial cells constitutively expressed very low levels of LIF mRNA,
barely detectable by Northern blot analysis. Strong induction of LIF
mRNA expression was caused by cytokines, such as interleukin-l/3 (5
ng/ml), tumor necrosis factor a (100 ng/ml) and PDGF (100 ng/ml), as
well as LPS (200 ng/ml). The induction was transient with a peak after
three to five hours. Dexamethasone (0.1 LM) almost completely inhib-
ited the induction of LIF. Weak induction of LIF mRNA was observed
after stimulation with basic fibroblast growth factor, endothelin and
transforming growth factor . In combination with IL-I p, TGF/3
showed synergistic effects on LIF induction. LIF itself or IL-6 had no
effect on LIF mRNA expression. A similar induction pattern was
observed for the expression of IL-6 mRNA. LIF protein was detected
by specific ELISA in the supernatants of human mesangial cells
stimulated with LPS or IL-l/3. In addition, we found that mesangial
cells not only express LIF but they are also target cells for LIF,
Recombinant LIF effectively induced transient expression of the im-
mediate early genes, c-fos,jun-B and Egr-l in rat mesangial cells, with
a maximum at 30 to 60 minutes. LIF was not mitogenic for mesangial
cells. Our findings indicate that glomerular mesangial cells produce and
react to LIF. As a cytokine with autocrine potential, LIF may play a
physiological and/or pathophysiological role in the glomerulus, the
exact nature and relevance of which remain to be explored.
Leukemia inhibitory factor (LIF) belongs to a group of
pleiotropic factors such as IL-6, G-CSF, IL-Il and oncostatin
M, which exert multiple effects on a great variety of embryonic,
developing or neoplastic cells of different origin [1—3]. LIF is a
polypeptide with a molecular mass of 20 kDa. Native LIF is
highly glycosylated but its biological activity appears to be
independent of glycosylation [1, 4, 5]. While immature cells
seem to be important target cells for LIF, this cytokine has also
been shown to act on terminally differentiated cells such as
certain peripheral blood cells [3, 6], hepatocytes [7, 8], bone
cells [9] or adipocytes [10]. The functional role of LIF in these
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cell systems varies considerably, ranging from the inhibition of
lipoprotein lipase [10] to the stimulation of calcium release from
bone tissue [11, 12]. LIF is involved in the regulation of platelet
formation, osteoblast and neuronal cell functions, calcium and
lipid metabolism, tumor related cachexia and the production of
acute-phase proteins [11.
At present, the molecular mechanisms of signal transduction
and the intracellular targets of LIF are largely unknown,
although one endpoint of the cascade, the LIF responsive
element, has recently been mapped [13]. The half-life of LIF in
plasma is short (3 to 5 mm) and it is therefore considered a
locally acting cytokine [1].
So far, most studies on the expression or action of LIF in
vitro have been performed with immature cells or cell lines.
Expression of LIF in the adult organism is restricted to certain
organs or mature cell types [14]. LIF mRNA was detected in
activated normal T cells and certain T cell lines but not in B
cells or granulocytes [15]. Upon activation, LIF is released into
the supernatants of cultured human monocytes [16]. LIF is
constitutively expressed in several human mesenchymal cells
(fibroblasts and endothelial cells) [15]. In these cells, expression
of LIF was found to be enhanced by the inflammatory cytokines
interleukin I /3 (IL- 1/3) and tumor necrosis factor a (TNFa).
Recently, LIF was shown to be expressed in human cartilage
and synovium. Its expression in these tissues was stimulated by
several cytokines and also by LIF itself [17].
Induction of LIF expression often occurs in parallel with
induction of interleukin 6 (IL-6) expression [14]. LIF and IL-6
are induced by LPS, and glucocorticoids prevent this induction
in macrophages and hepatoma cells (Baffet and Fey, unpub-
lished data). In the kidney, only IL-6 expression has been
demonstrated in glomeruli and primary cultures of renal mesan-
gial cells [18—21]. Relatively high levels of LIF mRNA were
detected in neonatal rat kidney, but no comparison to adult
kidney was made [22]. The development of Na-dependent
hexose transport was found to be inhibited by LIF in the renal
epithelial LLC-PK1 cell line, indicating a role for LIF in the
developing kidney [23]. The expression of IL-6 in mesangial
cells supports the hypothesis that these cells might also express
LIF, and that LIF might be involved in the pathophysiology of
the kidney as has been suggested for IL-6 [21, 24, 25].
Here we report that LIF is expressed in mesangial cells of
human and rat origin. Its expression is stimulated in a cell
specific manner by LPS and certain cytokines, such as IL-lp
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and platelet-derived growth factor (PDGF), while neither IL-6
nor LIF itself are inducers of LIF in these cells. Similar to IL-6,
LIF also activates mesangial cells in an autocrine manner to
express immediate early genes, suggesting a potential role for
this cytokine in renal physiology and pathology.
Methods
Materials
CHO cells transfected with recombinant human LIF were
provided by Genetics Institute (Cambridge, Massachussetts,
USA). The supernatant of these cells was used as a source of
LIF activity. The concentration of LIF in these supernatants
was approximately 2 jsg/ml LIF protein as determined with a
commercially available ELISA (R&D Systems, Minneapolis,
Minnesota, USA), corresponding to 500 U/p! determined with
the FAO/HB3 assay [13]. For stimulation of mesangial cells or
embryonic stem cells, LIF was used at a final concentration of
approximately 2 ng/mI. LPS from E. coli, serotonin (5-HT) and
cycloheximide were from Sigma (Deisenhofen, Germany), ba-
sic fibroblast growth factor (bFGF), PDGF (BB) and human
IL-6 were from Boehringer (Mannheim, Germany), endothelin
from Sigma, transforming growth factor p (TGFJ3) from Gibco-
BRL (Eggenstein, Germany). TNFa with a specific activity of 8
x 106 U/mg was provided by BASF/Knoll (Ludwigshafen,
Germany), recombinant human IL-1f3 with a specific activity of
2 x iO U/pg was provided by D. Borasci, Sclavo (Siena, Italy).
3H-thymidine was purchased from Amersham Buchler (Braun-
schweig, Germany). Embryonic stem cells were obtained from
V. Quaranta (La Jolla, California, USA) [26], buffalo rat liver
cells (BRL cells) were from American Type Culture Collection.
Cell culture
Rat mesangial cells were isolated and cultured as described
[27]. The cells showed the typical smooth muscle cell-like
morphology and positive immunocytochemical staining for Thy
1.1, smooth muscle cell actin and myosin. Cells were grown in
Dulbecco's Modified Eagle Medium (Gibco) containing 10%
FCS (Gibco), 5 tg/ml insulin, 100 U/mI penicillin, 100 g/ml
streptomycin and 2 mi L-glutamine (Sigma) in a 95% air, 5%
CO2 humidified atmosphere at 37°C. The cells were used for
experiments between passages 7 and 15. Subconfluent cultures
were serum-starved for four days with DMEM containing 0.5%
FCS before stimulation.
Whole glomeruli were isolated as described [27] and trans-
ferred into cell culture flasks (30,000 each) with DMEM con-
taining 0.5% FCS. The isolated glomeruli were stimulated with
10 g/ml LPS. After five hours glomeruli were washed twice
with PBS and homogenized in guanidinium isothiocyanate with
a Dounce homogenizator. RNA was prepared and Northern
Blot analysis was performed as described below.
Human mesangial cells were isolated from histologically
normal human kidneys as described by Radeke et a! [28]. The
cells stained positive for Thy 1.1 and smooth muscle cell actin.
They were cultured in RPM! (Biochrom, Berlin, Germany) with
20% FCS and 1% insulinltransferriniselen cocktail (Biochrom).
Passages 3 to 6 were used for experiments and serum starvation
was carried out in RPM! containing 1% FCS for three days.
Determination of cell proliferation
Cell proliferation was estimated by 3H-thymidine uptake.
Mesangial cells were seeded in 96-well microplates. At subcon-
fluence, mesangial cells were growth-arrested in DMEM con-
taining 0.5% FCS for four days. After adding agonists to the
mesangial cells, DNA synthesis was followed by labeling the
cells with 3H-thymidine (2.5 CiIml) for the times indicated. At
the end of the labeling period, mesangial cells were washed
twice with PBS, trypsinized with 0.05% trypsine and 0.02%
EDTA, and harvested onto cellulose filters with an automated
cell harvester (Cambridge Technology, Watertown, Massachu-
setts, USA). Finally, the filters were counted in a Beckman rack
scintillation counter.
Determination of protein synthesis
Protein synthesis was measured by leucine incorporation.
Mesangial cells were seeded in 24-well plates. At subconflu-
ence, they were growth-arrested in DMEM containing 0.5%
FCS for four days. Cells were then stimulated with the agonists
and leucine incorporation was determined similar as described
by Freshney [29].
Isolation of RNA and Northern blot analysis
Cellular RNA was isolated by the guanidinium isothiocyanate
method as described [30]. Twenty micrograms RNA were
loaded on a 1% agarose/1 .8% formaldehyde gel, size fraction-
ated and transferred to a nylon membrane (Hybond N, Amer-
sham, Braunschweig, Germany) with 2OxSSC overnight.
Ethidiumbromide staining of the gel and membrane confirmed
equal loading and sufficient blotting of the RNA. The RNA was
fixed by baking for two hours at 80°C. The blots were probed
with a 300 bp rat LIF cDNA fragment (bp 5096 to 5306 of the 3.
exon of rat LIF gene) purified with Geneclean Kit (Dianova,
Hamburg, Germany) from plasmid pLIF-PBS after digestion
with PstI and EcoRI (Baffet and Fey, unpublished data).
For detection of IL-6 mRNA, a full length rat cDNA was
used (pRIL6C.94) [31]. The GAPDH hybridization control was
carried out with a 500 bp reverse transcribed fragment, ampli-
fied from rat mRNA using the following PCR primers: sense
primer 5'-AATGCATCCTGCACCACCAA, antisense primer
5'-GTCATTGAGAGCAATGCCAGC. cDNA probes for jun-B
(mouse) and c-fos (mouse) were obtained from Dr. Bravo
(Princeton) and for Egr-l (mouse) from Dr. Sukhatme (Boston).
mRNA sizes were evaluated by comparison with l8S and 28S
rRNA. The sizes of the relevant mRNAs were: c-fos 2.3 kb,
jun-B 2.1 kb, Egr-1 3.4 kb, GAPDH 1.4 kb, LIF 4.3 kb, and IL-6
2.4 kb and 1.2 kb.
DNA fragments were labeled with 32P-dCTP using a random
priming kit (Amersham). Prehybridization was performed at
42°C for two hours with a buffer containing 5 x SSC, 3 M NaCl,
0.3 M Na citrate, 0.1% SDS, SxDenhardt's solution, 50 mM
Na2HPO4 (pH 6.5), 50% deionized formamide and 250 g/ml
denatured salmon sperm DNA. Hybridization was carried out
under the same conditions for 12 to 24 hours. The membranes
were washed twice with 2xSSC/0.1% SDS at 40°C for 15
minutes and twice with 0.2xSSC/0.1% SDS for 30 minutes at
the same temperature. Blots were then exposed to a Kodak
X-ray film with intensifying screen for varying time periods.
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Autoradiographs of Northern blots were quantitated densito-
metrically. mRNA signals were corrected for GAPDH mRNA
expression to confirm equal loading of RNA.
RT-PCR
Complementary DNA was synthesized using 0.5 jsg of total
RNA with oligo dT16 as downstream primer according to the
protocol of the Perkin Elmer Cetus GeneAmp RNA PCR Kit,
using 1 mM 3-mercaptoethanol in the RT reaction. The cDNA
was then amplified with specific primers for human LIF (sense
primer 5'-GATGAGTCCAAGATAGAGAGC, and antisense
primer 5'-CCTGACCCTAAGTTCTGC) provided by Dr.
Schrell (Erlangen), and control primers for human cyclophilin
(sense primer 5'-CATCTGCACTGCCAAGACTG, and an-
tisense primer 5'-CTGCAATCCAGCTAGGCATG). PCR reac-
tion was carried out according to the Perkin Elmer protocol for
30 cycles with one minute at 94°C, one minute at 55°C and three
minutes at 72°C. The PCR products were size fractioned on an
1.8% agarose gel and detected by ethidium bromide staining.
(LIF: 516 base pair signal, cyclophilin: 326 base pair signal).
Performing the RT-PCR without adding reverse transcriptase,
there was no detectable signal, confirming that no DNA was
amplified.
Determination of LIF protein
The concentration of LIF protein in the CHO cell superna-
tants was determined with a commercial ELISA (R&D Sys-
tems). The same ELISA was used for the determination of LIF
protein in culture supernatants of human mesangial cells. Su-
pernatants were concentrated 20-fold by overnight centrifuga-
tion with CentriconlO (Amicon, Witten, Germany).
LIF bioassay
Biological activity of LIF was measured using an embryonic
stem (ES) cell assay [321. These cells are known to proliferate in
LIF-containing medium. In the absence of LIF, they develop
into differentiated cells within two to three days. ES cells (l0
cells per well) were grown in gelatin-coated 24-well plates in
DMEM with 10% FCS, 1% glutamine, 1% mercaptoethanol and
500 U/mI LIF (CHO supernatant). For use in the LIF assay, the
cells were washed twice in PBS and cultured in the presence of
the test samples (various concentrations of mesangial cell
supernatants) for 36 hours.
Results
Detection of LIF mRNA in rat mesangial cells and isolated
glomeruli
Rat mesangial cells were grown to subconfiuence in the
presence of 10% FCS. Resting cells were obtained after four
days of culture in medium containing only 0.5% FCS. Under
both conditions, there were only trace amounts of LIF mRNA
detectable by Northern blot analysis (Fig. 1). Restimulation of
resting mesangial cells with 10% FCS led to the induction of the
4.3 kb LIF mRNA. As a control, buffalo rat liver cells were
used which constitutively expressed small amounts of LIF
mRNA [33]. After serum deprivation and restimulation for
three hours, these cells expressed LIF mRNA of the same size
(Fig. 1). Stimulation of growing or resting mesangial cells with
the bacterial wall component LPS (10 j.gIm1) led to a strong
FCS - FCS LPS LPS -
A R R R G G
Fig. 1. Expression of LIF mRNA in growing and growth-arrested rat
mesangial cells. Growing (G) or growth arrested (R) mesangial cells
were incubated with LPS (10 g/ml) or FCS (10%), as indicated. As a
control, growth arrested buffalo rat liver cells (BRL cells) were incu-
bated with 10% FCS. After 3 hours, cells were harvested and RNA
prepared as described in Methods. Northern blots were hybridized with
a LIF cDNA probe. Equal loading of the gel was confinned by the
ethidium bromide staining of the 28S ribosomal RNA. The blot shown
is representative for 3 similar experiments.
induction of LIF mRNA (Fig. 1). Resting mesangial cells
proved to be particularly sensitive to LPS: concentrations as
low as 2 ng/ml induced LIF mRNA to a degree similar to the
induction by jsg amounts of LPS (Fig. 2a). The cytokine IL-113
(5 nglml) was found to be another strong stimulus of LIF mRNA
induction (Figs. 2b, 3). Small amounts of LIF mRNA were also
detectable in freshly isolated glomeruli. Upon incubation with
LPS (10 jsg/ml) for five hours, LIF mRNA expression was
almost doubled (relative intensity of mRNA signals detected by
autoradiography: 0.64 vs. 0.38 with GAPDH as reference; data
not shown).
Transient induction of LIF mRNA and IL-6 mRNA
The time kinetics of the induction of LIF mRNA were
determined in growth-arrested rat mesangial cells with 10%
FCS, 5 jsg/ml LPS and 5 ng/ml IL-lf3 as stimuli (Fig. 3). The
FCS-induced mRNA expression was maximal after one to three
hours, then declined and was barely detectable after eight
hours. The kinetics of the induction by LPS and IL-1/3 were
very similar with a peak after five hours and a clear signal still
visible after eight hours. After 20 hours, background levels
were obtained in all cases. Interestingly, IL-6 mRNA was
induced by the same cytokines with the same kinetics as was
LIF mRNA (Fig. 3). Two species of IL-6 mRNA of 1.2 kb and
2.4 kb were detected, as described before [34, 35].
Effects of cycloheximide and dexamethasone on LIF and IL-6
mRNA induction
Inhibition of protein synthesis by cycloheximide in resting
mesangial cells led to a strong induction of LIF and IL-6
mRNA, comparable to the one caused by 10% FCS (Fig. 4).
The glucocorticoid dexamethasone interfered with the IL-113-
induced expression of LIF and IL-6 mRNA. For this type of
experiment, the cells were preincubated with dexamethasone
(l0 M) for two hours prior to the addition of IL-1/3 (Fig. 4).
BRL
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Fig. 2. Concentration-dependent induction of LIF mRNA by LPS and
IL -1 13. Resting mesangial cells were incubated with LPS (a) or IL-l/3 (b)
for 3 hours, as indicated. Autoradiographs of Northern blots were
quantitated densitometrically. The LIF mRNA signal was corrected for
GAPDH mRNA expression to confirm equal loading of RNA. The data
presented are representative for 2 independent experiments.
LIF mRNA concentrations were reduced to background values
while IL-6 mRNA expression was less sensitive to dexameth-
asone.
Induction of LIF mRNA by various cytokines
A number of cytokines were tested for their ability to induce
LIF mRNA expression. Concentrations were chosen, which
had been shown before to induce cellular responses (such as
proliferation or prostanoid synthesis) in the rat mesangial cells
used. Cytokines with very different cellular effects on mesangial
cells, namely IL-l/3 (5 ng/ml) or TNFa (100 ng/ml) and platelet-
derived growth factor (PDGF, 100 nglml), were found to induce
LIF mRNA (Fig. 5). A weak induction was also observed with
basic fibroblast growth factor (bFGF, 10 ng/ml), transforming
growth factor (TGFI3, 4 ng/ml), endothelin (l0— M) and epider-
mal growth factor (EGF, 60 ng/ml). When used in combination
with IL-l)3, TGFJ3 showed a strong synergistic effect on LIF
inRNA expression (Fig. 6). LIF (200 to 1000 U/mi) was not able
to induce its own message, nor was LIF mRNA induced by IL-6
(200 U/mi), or vice versa.
Detection of LIF mRNA in human mesangial cells
The rat cDNA for LIF did not cross react with mRNA
obtained from human mesangiai cells. Therefore, RT-PCR was
used to show LIF mRNA expression. In unstimulated, growth-
arrested human mesangial cells, very little LIF mRNA was
detectable. Upon incubation with LPS or IL-1J3, there was a
significant increase in LIF mRNA reflected in an increase in the
amount of PCR product (Fig. 7).
Induction of LIF protein release
To evaluate for secreted LIF activities, the supernatants of
stimulated rat mesangial cells were concentrated and intro-
duced into an ES cell bioassay. These cells grow in the presence
of LIF but differentiate when LIF is withdrawn [36]. The
mesangial cell supernatants did not support ES cell prolifera-
tion, but rather induced a rapid differentiation of the target
cells, most likely due to a combination of different growth
factors which are known to be secreted by activated mesangial
cells. Therefore, it was not possible to assess specific LIF
bioactivity by this assay.
Since no antibody reacting with rat LIF was available to us,
LIF protein was analyzed in the supernatants of human mesan-
gial cells only. Within five hours LPS (10 g/ml) induced a
twofold increase of LIF protein release: control 2.7 0.6pg/ml,
LPS 5.3 1.7 pg/ml (means range of 2 independent isolates
determined in duplicates). In two additional supernatants of
other isolates of human mesangial cells, the release of LIF in
controls was at or below the detection limit of the ELISA (0.7
pg/mI or less). Upon stimulation with IL-1f3 for 15 hours, large
10 amounts of LIF protein were released (5.0 0.7 pglml; means
range of 2 independent isolates).
Induction of the expression of immediate early genes by LIF
Resting rat mesangial cells were incubated with human re-
combinant LIF (2 ng/ml). A transient induction of the immedi-
ate early genes c-fos, Egr-l and jun-B was observed after 30 and
60 minutes (Fig. 8). Similar responses of mesangial cells were
obtained after stimulation with IL-6 (data not shown). In
control experiments, mesangial cells were incubated with PBS/
0.1% BSA. Such treatment of the cells did not lead to any
induction of immediate early genes.
Effects of LIF on mesangial cell proliferation
The mitogenic potential of LIF on mesangial cells was
studied by incubating resting rat mesangial cells with human
recombinant LIF (50 U/ml, 500 U/mI and 5000 U/mI) for 24, 48,
72 and 96 hours. Cell proliferation was measured by 3H-
thymidine incorporation for the last 24 hours. As shown in
Figure 9, no increase of mesangial cell proliferation was in-
duced by LIF at the concentrations tested. In combination with
known mesangial cell mitogens such as PDGF (25 ng/mi) and
5-HT (1 SM), LIF caused a slight increase in 3H-thymidine
incorporation after 24 hours. The PDGF-induced thymidine
incorporation was enhanced 1.32 0.06-fold (means SD, N =
5 independent experiments, P < 0.001). The interaction with
5-HT was less significant (1.19 0.13, N = 5, P < 0.05). The
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Fig. 3. Time course of the induction of LIF and IL-6 mRNAs. Growth-arrested mesangial cells were incubated with FCS (10%), IL-l/3 (5 ng/ml)
or LPS (5 gIml) for the times indicated. Northern blots were probed consecutively with LIF and IL-6 cDNAs. Equal loading was confirmed by
ethidium bromide fluorescence and hybridization with a GAPDH cDNA probe. Data shown are representative for 4 experiments.
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Discussion
parallel in many cells and tissues. Only IL-6 has been known to
be expressed and produced by mesangial cells in culture, while
no information has been available about expression of LIF in
mesangial cells or other kidney cells. Our results demonstrate
that rat and human glomerular mesangial cells in culture ex-
press LIF, In addition, LIF mRNA was also detectable in
- 4 3 kb freshly isolated whole glomeruli. We found very little LIF
mRNA expressed in resting mesangial cells and in mesangial
cells growing in an unsynchronized fashion. LIF was tran-
siently induced by various stimuli, including FCS, the bacterial
- 2.4 kb wall component LPS, inflammatory cytokines such as IL-113 or
TNFa, or the mitogen PDGF. These diverse stimuli have
previously been reported to induce IL-6 in mesangial cells
[17—19], which was confirmed in our studies. In other organs,
- 1.2 kb such as liver [37], LIE and IL-6 have been shown to share many
but not all properties. Their receptors associate with the same
transducing protein, gpl3O [38]. In hepatocytes, the same
response element in the promoter of the a2-macroglobulin gene
is activated by IL-6 and LIF, indicating that both use the same
signal transduction cascade [13]. Diverging functions of LIF
- 1.4 kb and IL-6 have also been observed. As discussed below, IL-6
has been implicated in glomerular pathology, while a functional
role of LIF in the kidney remains to be elucidated. At present it
is unclear to which extent these cytokines possess overlapping
or differential characteristics in the kidney. LIF has been
discussed to be involved in inflammatory reactions. Urinary
excretion of LIF was found elevated during acute kidney graft
rejection [39], but the origin of LIF production remained
unclear. LIF production was studied in detail in the inflamed
joint, where its synthesis was increased by IL-l/3 and TNFa
[17, 40]. The present results demonstrate that these cytokines
are also able to induce LIF in mesangial cells, suggesting a role
for LIF in glomerular inflammatory reactions, as has been
discussed for IL-6 [24, 41].
LIF mRNA was barely detectable by Northern blot analysis
in growth arrested or proliferating mesangial cells. Induction of
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Fig. 4. Effect of cycloheximide and dexamethasone on LIF and IL-6
mRNA expression. Growth-arrested mesangial cells were incubated
with FCS (10%), cycloheximide (CHX, 50 Lg/ml), IL-lf3 (5 nglml) or
dexamethasone (10—v 54) for 3 hours; control lane: cells incubated with
PBS/0. 1% BSA. Northern blot analysis was performed with probes for
LIF, IL-6 and GAPDH.
increase of thymidine incorporation disappeared after 48 hours.
LIF by itself had no significant effect on total protein synthesis
as determined by leucine incorporation. The PDGF-induced
increase of leucine uptake was not augmented by LIF.
LIF is a polyfunctional cytokine which shares many charac-
teristics with IL-6. Expression of LIF and IL-6 is regulated in
4 
Sh
r 
5h
r 
8 
hr
 
20
 h
r 
lh
r 
3h
r 
4 
8h
r 
2O
hr
 
1 
hr
 
3 
hr
 
5 
hr
 
Bh
r 
20
 h
r 
a
•*00
Hartner et a!: Leukemia inhibitory factor 1567
LIF
GAPDH
U U) (0(.:, 0w -J — -J
C
a)
..- 0U) U- U • D0 ( Z 0
U- F- I— 0 w
LL
0
- 4.3 kb
-1.4kb
Fig. 5. Effect of various mesangial cell stimuli on LJF mRNA expression. Growth-arrested mesangial cells were incubated with IL-113 (5 ng/ml),
bFGF (10 nglml), EGF (60 ng/ml), LPS (5 sgIml), IL-6 (200 U), LIF (500 U), TGFI3 (4 ng/ml), TNFa (100 ng/ml), endothelin (10—v M) or PDGF
(100 ng/ml) for 3 hours; control lane: cells incubated with PBS/0. 1% BSA. Northern blot analysis was performed with probes for LIF and GAPDH.
Data shown are representative for 2 independent experiments.
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Fig. 6. Synergistic induction of LIF mRNA by IL-1/3 and TGF/3.
Growth-arrested mesangial cells were incubated with TGFI3 (5 ng/mI),
IL-1/3 (5 ng/ml), or TGFI3 and IL-1/3 together for 3 hours, and with
IL-113 for 3 hours after preincubation of 2 hours with TGF3. Control
lane: cells incubated with PBS/0.l% BSA, Northern blot analysis was
performed with probes for LIF and GAPDH.
LIF mRNA in mesangial cells was caused by LPS and a number
of cytokines with very different cellular functions in these cells:
PDGF is a strong mitogen while LPS, IL-l$ and TNFa activate
mesangial cells to secrete inflammatory mediators [42]. Induc-
tion of LIF mRNA by LPS and IL-lf.3 also resulted in secretion
of LIF protein, suggesting a biological significance. Another set
of bioactive compounds, namely endothelin, EGF, bFGF and
TGF/3, were only weak inducers of LIF mRNA expression. It is
not yet clear whether these changes in mRNA levels also
translated into significantly increased protein levels. The weak
induction was not due to insufficient concentrations of the
respective stimuli, since in control experiments we had shown
that they were able to activate mesangial cells by enhancing the
release of lipid mediators or by induction of proliferation, at the
concentrations used for induction of LIF (data not shown). A
strong effect of TGF/3 on LIF expression was detected only
when mesangial cells were stimulated with the combination of
TGF/3 and IL-113. Though almost ineffective by itself, TGFJ3
synergistically enhanced the ILl-p induced expression of LIF.
Synergistic actions of cytokines are commonly observed and
were described for LIF induction in synovial fibroblasts [401.
LIF mRNA was also induced by cycloheximide, suggesting a
role for labile proteins in the regulation of LIF mRNA expres-
sion and/or stability.
Neither IL-6 nor LIF itself was able to induce LIF mRNA,
arguing against an autocrine induction of LIF expression in
mesangial cells. Our data reveal that the inability to induce LIF
expression was not due to missing receptors of IL-6 or LIF
since both cytokines induced the expression of immediate early
genes. These results on mesangial cells differ from recent
observations in cartilage cells. A strong autoinduction of LIF
was found in neonatal and adult chondrocytes [17]. In addition,
LIP also induced IL-6 mRNA expression in these cells as well
as in human monocytes, synoviocytes and various cell lines
[43].
Cell-specificity is also indicated by the observation that
cytokine-induced LIP expression varies considerably between
different types of primary cultures: TGFI3 and bFGF are strong
inducers of LIP expression in chondrocytes [17], but only
weakly effective in synovial fibroblasts [40] and mesangial cells.
PDGF, a strong mitogen for all three cell types, induces LIF
mRNA in mesangial cells and chondrocytes, but not in synovial
fibroblasts. The mechanisms responsible for this apparent cell
specificity of LIF expression and its potential biological signif-
icance remain to be elucidated.
Once secreted, LIP could either act in an autocrine fashion
on mesangial cells or on the neighboring cells, such as glomer-
ular endothelial or epithelial cells. So far, no data are available
analyzing effects of LIP on glomerular endothelial or epithelial
cells. However, our results indicate an autocrine potential of
LIP in mesangial cells. LIF had no effect on total protein
synthesis as determined by leucine incorporation, but specifi-
cally induced a set of immediate early genes, c-fos, jun-B and
Egr-1. Early response genes have also been shown to be
induced by LIF in sympathetic neurons [44], in Ml myeloid
leukemia cells [45] and liver cells [37]. The induction of these
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Fig. 7. Detection of LIP mRNA in human
mesangial cells. Growth-arrested human
mesangial cells were incubated with LPS or
IL-l/3 for 3 hours. Control cells were
incubated with PBSIO. 1% BSA. PCR was
performed with LIF and cyclophilin (cyc)
primers in parallel. Left and right 4 lanes
show PCR products from two independent
experiments.
Fig. 8. induction of immediate early genes by
LIP in rat mesangial cells. Growth-arrested
mesangial cells were incubated with LIF for
the times indicated. Northern blots were
analyzed for Egr-l, c-fos, jun-B and GAPDH
mRNA. The blots are representative for 3
independent experiments.
genes could be a very early step in the signal transduction
pathway which will then diverge to initiate different cellular
responses depending on the cell type. The biologic response
induced by LIF in mesangial cells and its physiological or
pathophysiological relevance are still unknown. Induction of
immediate early genes, especially Egr- 1, has been discussed as
an early event in the mitogenic signaling cascade in mesangial
cells [46]. A correlation was found between the mitogenic
activity of vasoactive compounds and their ability to induce
Egr-l expression. In our experiments, neither LIF nor IL-6
were essential for mesangial cell proliferation. We were unable
to induce proliferation by either stimulus in resting rat mesan-
gial cells during a time period of up to six days. These findings
are in accordance with studies in rabbit aorta smooth muscle
cells, in which only oncostatin M, but not LIF or IL-6, was
mitogenic [47]. In the present experiments, LIF only showed a
transient effect on the PDGF-induced thymidine incorporation,
but no significant co-mitogenic effect on cell proliferation.
There are conflicting reports on the mitogenic potential of IL-6
in mesangial cells [48]. Depending on the experimental design,
IL-6 either promoted [24] or inhibited mesangial cell prolifera-
tion [49]. There is indirect evidence that IL-6 plays a role in
proliferative glomerulonephritis [24]; however, the precise in-
volvement of this cytokine in the glomerular inflammatory
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Fig. 9. Effect of LIF on 3H-thymidine incorporation by rat mesangial cells. Resting mesangial cells were incubated with 50 U/mI, 500 U/mi and
5000 U/mI LIF. DNA synthesis was followed by labeling the cells with 3H-thymidine from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours and 72 to
96 hours. Control cells were incubated with PBS. Data shown are means SD of 6 parallel wells and are representative for 3 experiments.
response is presently unclear. On the other hand, the LIF-
induced expression of immediate early genes in mesangial cells
may initiate biologic responses other than proliferation in these
cells, such as activation of synthesis and secretion of proteins.
Recently, Richards et al [50] described a selective up-regulation
of metalloproteinase inhibitor (TIMP-l) by LIF, IL-6 and
especially oncostatin M in fibroblasts. Similar effects of LIF on
the turnover of matrix proteins might also be relevant in
mesangial cells.
Infiltrating monocytes or other bone marrow-derived cells are
also potential targets of LIF in the glomerulus. LIF has been
shown to mediate chemoattraction of eosinophils [51] and to
induce gene expression and protein synthesis of macrophage
chemoattractant protein 1 (MCP-l) in chondrocytes [52]. Pre-
liminary data from our laboratory suggest similar effects of LIF
in mesangial cells (Hartner et al, unpublished observations).
Thus, LIF may be involved in the recruitment of immune
competent cells to the glomerulus once it has been induced by
inflammatory stimuli, such as TNFa and IL-1/3, or by the
exposure to bacterial products.
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